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INTRODUCTION
The immunoglobulin (Ig) molecule on the surface of a
clonal B-cell non-Hodgkin’s lymphoma (NHL) can be used
as a tumor-specific target for immunotherapy [1]. Each
tumor expresses a unique Ig receptor that contains a speciﬁc
antigen-recognition region (the idiotype [Id]). This Id pro-
tein can be recognized as a strong antigen by a different
species, but is a weak antigen in autologous systems [1-4].
Murine models have shown that vaccination with a tumor-
specific idiotype can prevent the growth of inoculated
tumors [2,4,5]. In clinical evaluations, patients treated with
Id vaccines who mount specific anti-Id immune responses
have experienced significantly prolonged remissions and
survival compared to patients who do not mount such
responses [6] or compared to historical control subjects.
Furthermore, there has been evidence of a molecular
response following Id vaccination, in which polymerase
chain reaction (PCR)-detectable tumor markers present
before vaccination can no longer be found after such ther-
apy [7,8]. Randomized controlled trials designed to define
the efﬁcacy of Id vaccination are in progress.
A strong inverse correlation exists between the presence of
a radiographically detectable tumor at the time of vaccination
and the laboratory detection of a cellular or humoral Id-spe-
ciﬁc immune response [6]. The apparent increase in immune
responsiveness of patients in complete remission at the time of
vaccination suggests that a vaccine approach would be most
effective in patients with minimal or no detectable residual
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ABSTRACT
Vaccination with the idiotype (Id) protein derived from B-cell malignancies can produce Id-specific immune
responses that correlate with improved remission duration and survival rates in patients with follicular non-Hodgkin’s
lymphoma (NHL). A state of minimal or no residual disease correlates strongly with the laboratory detection of a
cellular or humoral immune response. High-dose cytotoxic therapy (HDCT) with autologous stem cell support
(autologous bone marrow transplantation [ABMT]) can provide profound cytoreduction of B-cell NHL, but the
potential immune suppression associated with myeloablative therapy may compromise a patient’s ability to mount a
specific immune response. To determine whether patients with NHL could mount detectable immune responses
following ABMT, Id vaccines were administered at 2 to 12 months following myeloablative therapy to a series of
patients with relapsed or resistant B-cell NHL. Two different vaccination strategies produced robust immune
responses against KLH in all patients, supporting the capacity of the reconstituted immune system following
HDCT to react against a strong antigen. Combining the results from both vaccination strategies, 10 of 12 patients
mounted Id-specific humoral or cellular responses. Vaccinations were consistently well tolerated. Of the 12
patients, 7 have experienced prolonged remissions with a follow-up from HDCT ranging from 3 to more than 11
years. Our experience serves to document the ability of the recovering immune system to react against both self and
xenotypic antigens and supports the feasibility and safety of antigen-specific vaccination following myeloablative
therapy in patients with B-cell NHL.
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disease. The administration of high-dose chemotherapy with
stem cell rescue to achieve maximal cytoreduction is a logical
extension of this approach, potentially allowing for an
improvement in the efﬁcacy of Id vaccination.
However, there are theoretical concerns that immune
reconstitution may be incomplete in the months following
such therapy, potentially limiting a patient’s ability to mount
a signiﬁcant and antigen-speciﬁc immune response. Current
data addressing this issue are limited. There are decreases in
Ig levels for a period of months to years [9] and a prolonged
alteration in the normal T-cell profile [10,11] following
high-dose cytotoxic therapy (HDCT). Results from vaccina-
tions for infectious disease in the allotransplantation setting
suggest that the recovering immune system is able to mount
immune responses against infectious agents after 3 months
of recovery [12]. Vaccinations with an inactivated varicella
vaccine given only 1 month post–marrow infusion can
induce cellular immunity, and 3 monthly administrations of
vaccines have been able to reduce the severity of viral reacti-
vation [13]. In the autologous transplantation setting,
cytolytic T-cell responses against Epstein-Barr virus (EBV)-
transfected cell lines also recover within 3 months [14].
Humoral responses against strong xenoantigens, such as
murine proteins and plant toxins, develop with intravenous
exposure 4 months post–marrow infusion [15]. In a murine
syngeneic marrow transplantation model, immunity against
the idiotype can be generated in the donor and transferred
to the recipient with consequent protection from tumor
challenge [16,17]. However, there is a paucity of similar data
on vaccination against tumor antigens after myeloablative
therapy with autologous stem cell support in humans.
To explore the practical feasibility of giving Id vaccinations
to patients with NHL following HDCT and to determine
whether such vaccinations could indeed induce measurable
immune responses in this setting, 2 different vaccination
regimens were employed. An initial patient cohort received
subcutaneous protein vaccinations of Id-KLH in adjuvant (a
formulation of Syntex aduvant formulation or SAF) [18], a
regimen we have used extensively that has been effective in
stimulating immune responses outside the myeloablative
setting [6,19]. When a practical technique to administer
antigen-primed dendritic-cell vaccinations was first devel-
oped [20-22], it proved to be a potent way to stimulate spe-
ciﬁc cellular immune responses that could induce regression
of lymphomas [7]. In a subsequent cohort, a regimen was
incorporated that combined both Id-pulsed dendritic cells
and subcutaneous protein vaccination following myeloabla-
tive therapy. The results suggest that patients are able to
mount strong and speciﬁc immune responses in response to
either vaccination regimen after HDCT, establishing the
feasibility of this approach.
MATERIALS AND METHODS
Patients
All patients had relapsed or refractory B-cell lymphoma
and all patients had developed rapid disease progression or
transformation, which supported the use of HDCT with
stem cell rescue. The myeloablative regimens varied by
institutional standard. They included both chemotherapy
and total body irradiation. Vaccination was initiated 2 to
12 months after transplantation, dependent on marrow
recovery (recovery of total white blood cell count to greater
than 3000 cells/mL and independence from transfusion) and
vaccine availability and followed 1 of the 2 administration
schedules described below. Patients have subsequently been
monitored both clinically and radiographically for relapse.
Vaccine Formulation
The Id protein was produced by fusion of fresh tumor
cells to a heterohybridoma (K6H6-B5) with subsequent
selection for the tumor-derived Ig protein (Id) as previously
described [23]. Id protein was conjugated to KLH with glu-
taraldehyde and administered in SAF adjuvant as previously
described [6,19]. Id-pulsed autologous dendritic-cell infu-
sions consisted of autologous mononuclear cells collected by
leukapheresis and enriched for dendritic cells by gradient
centrifugation in the absence of cytokines, as previously
described [7,22]. These cells were pulsed with whole Id pro-
tein over 36 to 40 hours and then reinfused into the patient
[7,24,25]. A total of 1 million to 10 million dendritic cells
(deﬁned by high expression of HLA-DR molecules but lack-
ing the lineage-speciﬁc markers for monocytes) were rein-
fused with each vaccination.
Vaccine Treatments
Vaccination was initiated 2 to 12 months following stem
cell reinfusion. Eight patients received Id-adjuvant vaccina-
tion alone. These patients received 5 subcutaneous vaccina-
tions, 4 given monthly with the ﬁfth administered as a boost
2 months after the fourth vaccination. Four separate
patients received a combination of dendritic-cell and Id-
adjuvant vaccinations by the following schedule: 2 protein-
pulsed dendritic-cell infusions followed by 5 Id-adjuvant
vaccinations, all given at monthly intervals.
Humoral Responses
Serum anti-Id antibodies were measured by enzyme-
linked immunosorbent assay (ELISA) as previously described
[6]. Brieﬂy, tumor Id protein and isotype-matched controls
were coated onto microtiter plates. F(ab′)2 fragments were
used when the tumor Id protein was of the IgG isotype. Pre-
and postimmunization sera were serially diluted and allowed
to bind to the plates. Antibody binding was detected by mouse
anti-human IgG horseradish peroxidase (HRP) (TAGO,
Burlingame, CA). Anti-KLH antibodies were detected by a
sandwich ELISA, using KLH as the target and HRP-labeled
KLH as the detection molecule. A 4-fold increase in anti-Id
antibody titer compared to the prevaccination serum level and
binding to irrelevant isotype-matched proteins was deﬁned as
positive. A titer greater than 0.5 µg/mL (determined by com-
parison of sample results to a standard curve of known con-
centrations of anti-KLH antibody) was considered positive for
induced anti-KLH antibodies.
Cellular Proliferation Assay
Proliferation of peripheral blood mononuclear cells in
response to Id protein was measured using [3H]-thymidine
incorporation as previously described [6,25]. Cells were
incubated with media alone as the control, or with whole pro-
tein (either tumor-derived Id or isotype-matched Ig as a speci-
ficity control) with the addition of fresh media containing
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interleukin (IL)-2 (Cetus Corporation, Berkeley, CA) so that
the final concentration of IL-2 was 30 IU/mL on day 3.
[3H]-thymidine was added to the culture on day 5, and cells
were harvested on day 6. Incorporation of more than 2 times
the background on 2 or more occasions was required for
interpretation as positive.
RESULTS
Patient Characteristics
Disease and treatment features of all 12 subjects are
listed in Table 1. All patients started the series of injections
within 1 year of HDCT. All patients had progressive disease
prior to their autologous bone marrow transplantation
(ABMT) and most had developed resistant lymphomas
deﬁned by disease progression during chemotherapy. Frac-
tionated total body irradiation (FTBI) was included as part
of the HDCT in 11 of 12 patients (all except Patient 4).
High doses of cyclophosphamide, ifosfamide, etoposide, or
BCNU were also given as part of the transplantation proce-
dures. All patients were in complete remission following
HDCT and prior to vaccination.
Of the 8 patients receiving 5 subcutaneous injections of
Id conjugated to KLH in SAF adjuvant, 4 had de novo inter-
mediate-grade disease, and 4 had disease that transformed
from indolent to more aggressive lymphomas. All had recov-
ered their peripheral white blood cell counts prior to vacci-
nation. Patient 7 received incomplete SAF (ISAF) as adjuvant
for all 5 vaccinations. ISAF lacks the antigenic protein thre-
onyl-muramyl dipeptide, but has been found to have compa-
rable efﬁcacy in stimulating immune responses [26].
Seven patients were enrolled into the dendritic-cell vacci-
nation trial, but 3 developed progressive lymphoma within
6 months of the HDCT procedure and were therefore
excluded from vaccination. Four patients received the
dendritic-cell vaccination regimen. All had indolent histolo-
gies at diagnosis, and only Patient 9 had disease that trans-
formed to a more aggressive histology at the point of tumor
progression. The first dendritic-cell reinfusion was given
approximately 6 months following ABMT. All 4 patients had
peripheral white blood cell counts that recovered to normal
levels by the time of vaccination. Patient 11 had failure of
engraftment of his megakaryocytic lineage with persistent
severe thrombocytopenia (20,000-30,000 platelets/mL)
despite experimental treatment with thrombopoietin. This
condition did not delay or signiﬁcantly complicate his vacci-
nation regimen beyond the need for prophylactic platelet
transfusions prior to the leukapheresis procedures.
Toxicities
All protein vaccinations were well tolerated. Patients
noted moderate fever, myalgia, and fatigue for several days
following the injections, with local erythema and tender-
ness lasting up to 1 week. No limiting, sustained, or
delayed toxicities were identified, and no patients required
any adjustment in formulation or schedule secondary to
toxicity. All reactions to vaccination were consistent with
prior experience, and were characteristic of the SAF adju-
vant alone [6].
The dendritic-cell infusions were not associated with
any infusional toxicities, consistent with prior experience
[7]. The subcutaneous protein vaccine formulation for this
protocol used ISAF (previously deﬁned) as adjuvant, which
was very well tolerated with mild local reactions of signiﬁ-
cantly milder severity compared to those with SAF. Each
patient who started a vaccination regimen completed it
without interruption, dose adjustment, or delay.
Immune Responses
Id-Adjuvant Vaccination. The patients who received
vaccination with Id coupled to KLH in adjuvant (Tables 1 and
2, Patients 1-8) all mounted robust immune responses (both
humoral and proliferative) against KLH (Table 2), support-
ing the capacity of the immune system following HDCT to
Table 1. Characteristics of Study Patients*
No. of Resistant Time From
Patient Prior to Last BMT to
No. Histology† Therapies‡ Chemotherapy?§ Vacc, mo
1 FSC/DLC 2 No 12
2 FSC/FLC 4 Yes 3
3 FSC/DLC 3 Yes 11
4 DLC 3 No 2
5 DLC 5 No 2
6 DLC 2 No 5
7 FM/IMM 2 Yes 6
8 FLC 3 No 11
9 FM/DLC 3 Yes 6
10 FM 2 Yes 6
11 FSC 4 Yes 6
12 FM 3 Yes 6
*BMT indicates bone marrow transplantation; Vacc, vaccination;
FSC, follicular small cleaved; DLC, diffuse large cell; FLC, follicular
large cell; FM, follicular mixed cellularity; IMM, immunoblastic. 
†Dual histologies denote transformation to more aggressive
classification. 
‡Including the cytoreductive regimen used immediately prior to
myeloablative therapy.
§Developed tumor progression during previous therapy.
Table 2. Immune Responses and Freedom From Progression*
Patient Anti-KLH Anti-Id
No. Humoral Proliferative Humoral Proliferative DFS,
y†
1 + + – + 11.5+
2 + + + – 8.0+
3 + + + – 9.0+
4 + + + – 1.3
5 + + + – 1.0
6 + + + – 6.5+
7 + + + – 6.0+
8 + + - – 5.8+
9 + + + – 2.6
10 + + + – 1.3
11 + + + + 4.5+
12 + + – – 1.0
*Id indicates idiotype; DFS, disease-free survival.
†DFS measured from myeloablative therapy to disease relapse.
Ongoing DFS is denoted by a plus sign (+). 
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react against a strong antigen. Seven of these patients also
mounted Id-speciﬁc humoral or cellular responses (Table 2).
Speciﬁc humoral responses against the idiotype could be
measured in 6 patients of the Id-adjuvant vaccination group.
Of the remaining patients, 1 developed a nonspeciﬁc response
(detectable IgG binding to both autologous Id and class-
matched control Ig), and 1 patient failed to develop any evi-
dence of stimulated humoral immunity. One of the 8 Id-
adjuvant vaccination patients developed signiﬁcant speciﬁc
cellular proliferative responses, and 1 developed a specific
response that was on the borderline of signiﬁcance. In total, 7
of 8 patients who received the Id-adjuvant vaccination devel-
oped either humoral or cellular Id-speciﬁc responses (Table 2).
Dendritic-Cell Regimen. The second group of patients
received the pulsed dendritic-cell and Id-KLH combination
regimen (Tables 1 and 2, Patients 9-12). All 4 patients
mounted both humoral and proliferative immune responses
against KLH following the conjugated-protein vaccinations
(Table 2). Three patients mounted specific humoral
responses against their Id proteins. Patient 11 made a speciﬁc
T-cell proliferative response. Patients 9 and 10 evidenced
particularly robust but nonspecific cellular proliferative
responses against the Id, with significant proliferation
against control class-matched Ig. Patient 12 did not mount
any measurable cellular response, although it is notable that
this patient provided signs of an increasing lymphoma bur-
den during the vaccination period and developed a clinical
relapse shortly after vaccination. This suggests that his
tumor was progressing subclinically even at the start of vac-
cination, which may have suppressed his ability to mount a
tumor-speciﬁc response. In total, 3 of 4 patients developed
either humoral or cellular Id-speciﬁc responses.
Clinical Follow-up
The median follow-up following Id-adjuvant vaccination
is >6 years after HDCT, ranging from 3 to >11 years. Only
2 of the 8 patients have relapsed, both early after completion
of the vaccinations with rapidly progressive aggressive-
histology disease. One patient who received the dendritic-
cell regimen continues without relapse, now for more than
4 years after HDCT.
Antigen Expression at Relapse. When possible, tumors
were sampled at relapse and assessed for expression of the
idiotypic antigen. None of the patients in the protein vacci-
nation trial had tumor available for evaluation. Of the
patients receiving the dendritic-cell vaccination, all 3 of the
tumors that relapsed after vaccination expressed the idio-
typic clone from their original indolent lymphoma, as
deﬁned by expression of the same Ig isotype and identity of
the complementary DNA (cDNA) sequence of the CDR3 of
tumor Ig heavy-chain cDNA.
DISCUSSION
Current therapeutic options for both indolent and
aggressive B-cell NHL are not curative for most patients
and innovative treatments are needed. Idiotype vaccination
shows promise in this disease, but experience suggests that
the presence of clinically detectable disease may block or
prevent the development of an immune response against the
vaccine, as evidenced by the low frequency of immune
responses identiﬁed in patients who had residual lymphoma
at the time of vaccination [6]. Based on these observations,
an effective approach will require either a more potent vac-
cine, or a more potent method to reduce the tumor burden.
High-dose chemotherapy, although not in itself curative for
the majority of patients, can provide maximal tumor reduc-
tion in most types of lymphoma, and may be a superior
preparative regimen for therapeutic antitumor vaccines.
Models of marrow transplantation have shown that the
murine immune system can reconstitute and mount efﬁca-
cious immune responses as early as 2 weeks after myeloablative
therapy [17,27]. These 2 studies represent experiments in a
syngeneic murine marrow transplantation model and suggest
that tumor-specific T-cell activation develops in the early
posttransplantation period with possible beneﬁcial effect on
tumor-free survival. Immunization in the immune reconstitu-
tion period may augment this effect [28]. These data suggest
that vaccines may be more effective at inducing antitumor
immunity in the posttransplantation immune recovery period
than in other clinical settings. Current evidence suggests that
immune reconstitution in humans following myeloablative
therapy recapitulates the establishment of immunity in the
neonatal setting [29]. Part of this process involves the gradual
recovery of a broad repertoire of B and T cells. The time
frame for this reconstitution is driven by both innate and
therapeutically administered cytokines. It is recognized that
even in an autologous setting a form of graft-versus-host dis-
ease can develop, consistent with a hyperactivity of immune
mechanisms, supporting the use of vaccination during the
recovery phase after myeloablation [30].
Clinical experience with vaccination after HDCT with
autologous marrow reconstitution is very limited. Attempts to
use a dendritic-cell vaccination regimen with multiple
myeloma have been successful in stimulating cellular Id-
speciﬁc immune responses in a small percentage of patients,
predominantly those in complete remission following HDCT
[25,31]. Unfortunately, HDCT may have only a limited abil-
ity to induce complete regressions in patients with myeloma.
In contrast, in B-cell NHL, it is frequently possible to achieve
complete remission after myeloablative therapy, even in those
patients with aggressive and multiply recurrent tumors.
The experience described herein clearly demonstrates
that the immune system can reconstitute its ability to
respond to both a strong xenoantigen (KLH) and a weak
autoantigen (Id) following HDCT with autologous stem cell
rescue. The majority of patients were able to mount
humoral responses, similar to those that correlate with
improved outcome in the nontransplantation setting [6].
Some patients were able to mount Id-speciﬁc cellular prolif-
erative responses. The patients did not show any clinical
signs of autoimmunity against Ig or other self antigens.
These observations all serve to support the potential for vac-
cination in the posttransplantation setting.
All patients studied had aggressive disease and would have
been expected to have a poor prognosis even in the context of
having received HDCT. It is encouraging that 7 of these
12 patients have experienced prolonged remissions. Neverthe-
less, it is not possible from this limited experience to determine
the contribution of the vaccine to this favorable outcome.
We cannot compare the 2 vaccine regimens within these
protocols due to the small numbers and nonhomogeneous
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patient population. The general experience and potency of
dendritic-cell vaccinations supports their continued experi-
mental development. With further improvement in vaccine
technology, possibly including more efficacious adjuvant
formulations, optimized dendritic-cell preparations, and the
addition of cytokines, our ability to induce immunity against
tumors will improve.
This experience suggests that vaccination in the post-
myeloablative setting is safe and feasible in patients with
NHL. In addition, patients in the posttransplantation set-
ting have immune reconstitution sufﬁcient to mount mea-
surable antitumor responses. Myeloablative therapy permits
the achievement of maximal tumor reduction and creates an
opportunity during the immunologic recovery period to
maximize the immune response against weak tumor-related
antigens. As our understanding of this immune recovery
increases, our ability to integrate immunologic manipula-
tions will provide an opportunity to optimize active
immunotherapy.
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